| HOME >> BIOLOGY >> TECHNOLOGY |
n Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
Safe Harbor Statement
This press release contains forward-looking statements including
without limitation statements related to the potential safety and efficacy
of SNS-595, SNS-032 and SNS-314, planned additional clinical testing and
development efforts, the timing of enrollment in clinical trials and the
announcement of clinical results. Words such as "look forward," "suggests,"
"may," "expects," "designed," "believe," "appears" and similar expressions
are intended to identify forward-looking statements. These forward-looking
statements are based upon Sunesis' current expectations. Forward-looking
statements involve risks and uncertainties. Sunesis' actual results and the
timing of events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and uncertainties,
which include, without limitation, the risk that Sunesis' drug discovery
and development activities, including enrollment and reporting of results,
could be halted significantly or delayed for various reasons, the risk that
Sunesis' clinical trials for SNS-595, SNS-032 and/or SNS-314 may not
demonstrate safety or efficacy or lead to regulatory approval, the risk
that preliminary data and trends may not be predictive of future data or
results, the risk that Sunesis' preclinical studies and clinical trials may
not satisfy the requirements of the FDA or other regulatory agencies, risks
related to the conduct of Sunesis' clinical trials and manufacturing of
SNS-595, SNS-032 and SNS-314 and risks related to Sunesis' need for
additional funding. These and other risk factors are discussed under "Risk
Factors" and elsewhere in Sunesis' annual report on Form 10-K for the year
ended December 31, 2006 and other filings with the Securities and Exchange
Commission.
'/>"/>
| SOURCE Sunesis Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |